Dotinurad is under clinical development by Fortress Biotech and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase I drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dotinurad’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dotinurad overview
Dotinurad (Urece) acts as urate re-absorption agent. It is formulated as tablets for oral route of administration. Urece is indicated for the treatment of gout and hyperuricemia.
Dotinurad (FYU-981) is under development for the treatment of gout and chronic kidney disease. It is administered through oral route as tablet.
Fortress Biotech overview
Fortress Biotech, formerly Coronado Biosciences, identifies, acquires, develops, and commercializes marketed pharmaceuticals and development-stage pharmaceutical product candidates. The company provides business, scientific, regulatory, and legal support for advancing the products or product candidates of its partner firms. It is a marketing partner for various branded drugs indicated for the treatment of radiation dermatitis, severe acne, athlete’s foot, inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and other skin infections. Fortress Biotech is headquartered in New York, the US.
For a complete picture of Dotinurad’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
